Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)

October 7, 2026 7:30 AM
Guggenheim analyst Vamil Divan reiterated a Buy rating and $287.00 price target on Johnson & Johnson (NYSE: JNJ).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments